TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04969809

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound of the jugular veins
Description: Ultrasound of the jugular veins to assess the thickness of the carotid intima media

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound of the jugular veins
Description: Ultrasound of the jugular veins to assess the thickness of the carotid intima media

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: addition of phenylalanine-free protein substitutes
Description: addition of phenylalanine-free protein substitutes for sufficient daily intake of essential amino acids and other vitamins and minerals and nutritional plan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: addition of phenylalanine-free protein substitutes
Description: addition of phenylalanine-free protein substitutes for sufficient daily intake of essential amino acids and other vitamins and minerals and nutritional plan
Study: NCT06545812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural steroid injection (ESI)
Description: Minimally invasive methods such as epidural steroid injection (ESI) with corticosteroids like Methylprednisolone, Levobupivacaine and Lidocaine according to the protocol of the institution. They reduce inflammation by inhibiting pro-inflammatory mediators and causing a reversible local anesthetic effect.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy for disc herniation
Description: BTL Laser therapy, BTL ultrasound therapy and BTL Transcutaneous electrical nerve stimulation - TENS
Study: NCT04438382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin Therapy
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV or PO
Study: NCT05009381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stylage XXL at enrollment
Description: Injection in the chin at enrollment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stylage XXL at Month 6
Description: Injection in the chin 6 months after randomization
Study: NCT05160311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Medical Treatment (OMT)
Description: Optimized Medical Drug Treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Optimized Medical Treatment (OMT)
Description: Optimized Medical Drug Treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent (DES) Coronary Angioplasty
Description: Percutaneous Angioplasty with DES
Study: NCT05857514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Indomethacin
Description: Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Pancreatic duct stenting
Description: Prophylactic pancreatic duct stenting with rectal indomethacin 100 mg for prevention of post-ERCP pancreatitis
Study: NCT04882189

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Images of the corneal endothelium will be obtained using specular microscopy at 1- and 3-months post cataract surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Images of the corneal endothelium will be obtained using specular microscopy at 1- and 3-months post cataract surgery.
Study: NCT05122741

Intervention type: DRUG
Intervention: P2Y12 Potent Inhibitor + Aspirin for STEMI patients
Description: Patients will undergo primary percutaneous coronary intervention and DAPT with potent P2Y12 inhibitor (ticagrelor or prasugrel + aspirin)

Intervention type: DRUG
Intervention: Clopidogrel + Aspirin for CCS patients
Description: Patients will undergo elective percutaneous coronary intervention and DAPT with non-potent P2Y12 inhibitor (clopidogrel + aspirin)
Study: NCT05194956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoral scan
Description: An intraoral scan is multiple images taken using an intraoral scanning device which results in a digital mould being taken of the participants mouth and bite. It works by systematically placing the scanner tip over the teeth and gums, whilst it constructs an image on screen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoral scan
Description: An intraoral scan is multiple images taken using an intraoral scanning device which results in a digital mould being taken of the participants mouth and bite. It works by systematically placing the scanner tip over the teeth and gums, whilst it constructs an image on screen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alginate impressions
Description: Alginate impressions are the conventional method of creating dental moulds for orthodontic records. A plastic tray is filled with an alginate material, which is placed into the mouth to take a mould of the teeth. This requires two moulds for both top and bottom arches. In addition, the participant would also bite into a warm piece of wax to record their bite.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alginate impressions
Description: Alginate impressions are the conventional method of creating dental moulds for orthodontic records. A plastic tray is filled with an alginate material, which is placed into the mouth to take a mould of the teeth. This requires two moulds for both top and bottom arches. In addition, the participant would also bite into a warm piece of wax to record their bite.
Study: NCT06417866

Intervention type: OTHER
Intervention: informed consent
Description: standard verbal and written informed consent

Intervention type: OTHER
Intervention: spine model
Description: standard verbal and written informed consent + visual spine model
Study: NCT05525780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-5001
Description: Depending on the cohort, volume will be varied to administer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched volume of placebo product will be administered to each subject in each cohort.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral cohort
Description: Single dose of Aricept tablet
Study: NCT04674735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APSLXR
Description: Oral coated tablets once a day for 60 days.
Study: NCT05508945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabond Prineo Skin Closure System
Description: synthetic mesh patch is positioned and lightly pressed over 50% of the surgical incision. 2-octyl cyanoacrylate liquid adhesive is evenly applied over the mesh and allowed to dry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silk
Description: SERI surgical scaffold with dermaFLEX backing is positioned over the remaining 50% of the surgical incision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Steri-Strip
Description: non-woven rayon with adhesive backing is applied to 50% of the surgical incision.
Study: NCT06213064

Intervention type: BEHAVIORAL
Intervention: Study Product, THC Product, Placebo
Description: Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 21-day product use period with a total of 9 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
Study: NCT05286437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
Description: Lenvatinib and letrozole will be given orally (PO) daily from Day -14, while pembrolizumab will be administered intravenously during week 1 of each 6-weekly cycle from Cycle 1 Day 1 (C1D1), with daily lenvatinib and letrozole.
Study: NCT04842526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib and irinotecan combined with temozolomide
Description: Anlotinib, 7mg/m2, PO, was given for 14 days and stopped for 7 days; Irinotecan, 50mg/m2, D1-5, IV; Temozolomide, 100mg/m2, d1-5, PO; Three weeks is a cycle.
Study: NCT05685953

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine OC-007
Description: Plasmid DNA vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl solution
Study: NCT06183671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JX09 or placebo SAD
Description: For Part 1 SAD: JX09/placebo in capsule will be administered as a single oral dose. The nominal dose escalation scheme for the cohorts is 1, 3, 10, 30, 100, and 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JX09 or placebo MAD
Description: For Part 2 MAD: JX09/placebo in capsule will be administered for 11 days (once daily) The nominal dose escalation scheme for the cohorts is 2, 5, 10 and 20 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JX09
Description: For Part 3 FE: JX09 in capsule will be administered as a two single oral doses separated by 15 days. The nominal dose is 10 mg.
Study: NCT04969224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed dose combination (FDC) tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study: NCT04834063

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Zinc a level
Description: Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Zinc a level
Description: Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: serum selenium level
Description: Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: serum selenium level
Description: Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan measurement
Description: Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan measurement
Description: Diagnostic test
Study: NCT05851040

Intervention type: OTHER
Intervention: Observation study
Description: Looking to find the role of wheatgrass and tulsi give separately or with allopathic drug

Intervention type: OTHER
Intervention: Observation study
Description: Looking to find the role of wheatgrass and tulsi give separately or with allopathic drug

Intervention type: OTHER
Intervention: Observation study
Description: Looking to find the role of wheatgrass and tulsi give separately or with allopathic drug
Study: NCT05895968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior cervical surgery
Description: The patients were operated by the posterior cervical surgery, which were used with the barbed to suture the deep fascia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior cervical surgery
Description: The patients were operated by the posterior cervical surgery, which were used with the barbed to suture the deep fascia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior cervical surgery
Description: The patients were operated by the posterior cervical surgery, which were used with the barbed to suture the deep fascia.
Study: NCT05639998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAXIN(BBV152)
Description: COVAXIN® on day 0 and on day 28 via the intramuscular route in GROUP 1. COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28:GROUP 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAXIN(BBV152)
Description: COVAXIN® on day 0 and on day 28 via the intramuscular route in GROUP 1. COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28:GROUP 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAXIN(BBV152)
Description: COVAXIN® on day 0 and on day 28 via the intramuscular route in GROUP 1. COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28:GROUP 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV154 Intranasal Vaccine
Description: BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28: GROUP 3 BBV154 on day 0 and on day 28 via the intranasal route: GROUP 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV154 Intranasal Vaccine
Description: BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28: GROUP 3 BBV154 on day 0 and on day 28 via the intranasal route: GROUP 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV154 Intranasal Vaccine
Description: BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28: GROUP 3 BBV154 on day 0 and on day 28 via the intranasal route: GROUP 4
Study: NCT06546761

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography and FFRct analysis
Description: A new non-invasive cardiac diagnostic test, coronary CT-derived fractional flow reserve (FFRCT) provides a unified anatomic and functional assessment of coronary artery disease which can reliably identify ischemia-producing coronary lesions. FFRCT accurately reflects invasively measured FFR and can help guide patient management and coronary revascularization decisions.
Study: NCT05819047

Intervention type: DEVICE
Intervention: Functional test with a haptic device
Description: Volunteers will complete two tests based on the Nine Hole Peg Test with a haptic device.
Study: NCT06351852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Neostigmine and Glycopyrrolate
Description: Transcutaneous

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Box by Dynatronics
Description: Electric field conducting drugs through the skin without compromising its integrity
Study: NCT06268496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serum formula 2039125 03
Description: application twice a day of the tested product (in the morning and evening) to the face for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serum formula 2039125 03
Description: application twice a day of the tested product (in the morning and evening) to the face for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serum formula 2039125 03
Description: application twice a day of the tested product (in the morning and evening) to the face for 3 months
Study: NCT05538923

Intervention type: OTHER
Intervention: No intervention was given to the patients
Description: This study was an observational epidemiological study.

Intervention type: OTHER
Intervention: No intervention was given to the patients
Description: This study was an observational epidemiological study.
Study: NCT05000853

Intervention type: DRUG
Intervention: Iron Carboxymaltose
Description: Iron supplementation when is needed according to usual care
Study: NCT05389826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth App
Description: We will compare the degree of improvement in phosphate control with respect to baseline values and report any adverse event. Nephrologist will use a web management system to provide results of phosphorus levels and medical recommendations to the patient, mediated by a cloud IT environment. In addition, patients will receive alerts, suggestions, and general information. They will also be able to communicate with nephrologists and interact with their corresponding group of fellow patients.
Study: NCT05229952

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-oxalate controlled diet
Description: Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium for 5 days. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primed, continuous intravenous infusion of 13C2-oxalate
Description: Participants will receive a continuous intravenous administration of carbon-13 oxalate, a naturally occurring form of oxalate, over the course of several hours until steady-state is achieved, using an IV catheter, while remaining fasting.
Study: NCT06730035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood analysis
Description: This is an experimental analysis on tissues (peripheral blood) and exploratory, which is why the enrollment of a limited number of patients has been planned. The results obtained from the study should not be considered conclusive but rather as generators of research hypotheses for potential subsequent studies to be conducted on larger populations. The qualitative and quantitative characteristics of the vesicles and their miRNA content will be analyzed descriptively.
Study: NCT06731231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are glucose lowering agents used in the treatment of type 2 DM by improving glycemic control, weight reduction, blood pressure control and albuminuria. the use of SGLT2i as a cardiorenal protective tool may be of particular value in renal transplant patients due to the risk of multiple comorbidities such as diabetes and hypertension. Recently, sodium-glucose transport protein 2 inhibitors (SGLT2i) emerged as a new class of therapeutics with beneficial effects on both cardiovascular (CV) and kidney outcomes in patients with diabetic kidney disease, nondiabetic proteinuric chronic kidney disease (CKD), and heart failure with and without diabetes in patients with native kidneys
Study: NCT06731257

Intervention type: OTHER
Group type: OTHER
Intervention: virtual ward early discharge
Description: Patients who are randomised to the study group will receive a blood pressure monitor and instructions on how to use the device and transfer data to the study team. The study nurses will contact the patient every day for 3 days following their discharge and perform an virtual ward round assessment by telephone (see table). This will determine whether the patient continues to be monitored via the virtual ward, or whether they need to be referred to the clinical team. They will be issued with an emergency contact number out of hours (coronary care unit LGI) and the nursing hub will operate from 8am to 5pm 7 days a week. They will be referred to the community cardiac rehabilitation service whilst on the pathway.
Study: NCT06731829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9231
Description: HRS-9231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9231
Description: HRS-9231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9231
Description: HRS-9231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadobutrol
Description: Gadobutrol
Study: NCT06730555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCESS Intervention
Description: Participants will receive the ACCESS intervention with funding, consisting of up to 16 hours of practice facilitation per month in person and/or virtually. Practice facilitation is training and support on implementation of routine HIV/HCV screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants will receive a link to the CDC compendium of evidence-based interventions for HIV prevention.
Study: NCT06730191

Intervention type: PROCEDURE
Group type: OTHER
Intervention: soft tissue graft covering immediate dental implant
Description: soft tissue graft covering immediate dental implant

Intervention type: PROCEDURE
Group type: OTHER
Intervention: soft tissue graft covering immediate dental implant
Description: soft tissue graft covering immediate dental implant
Study: NCT06016348

Intervention type: PROCEDURE
Intervention: Endovascular treatment
Description: This procedure is instrumental in restoring cerebral blood flow by addressing the clot-induced obstruction within brain-supplying blood vessels.

Intervention type: PROCEDURE
Intervention: Endovascular treatment
Description: This procedure is instrumental in restoring cerebral blood flow by addressing the clot-induced obstruction within brain-supplying blood vessels.
Study: NCT06014125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducative program
Description: The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks.~The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment.~The second session will focus on personalised hygienic and dietary measures. A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed.~A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment.~The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent.
Study: NCT04837105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious game ARROW CP
Description: ARROW CP is developed for Microsoft Hololens headset. Feedback on gait performance are delivering to the participant in real time and with delay. Participants have to walk at their maximal speed during sprint session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: Participant walk on a treadmill at 80% of their maximal speed during maximum 20 minutes (+5 min warm-up / 5 min cool-down)
Study: NCT06228833

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: monopolar radiofrequency
Description: Each subject underwent monopolar radiofrequency treatment (Thermage FLX ™ ) on both sides of the face

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monopolar radiofrequency
Description: Each subject underwent monopolar radiofrequency treatment (Thermage FLX ™ ) on both sides of the face

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinCeuticals A.G.E and Skinceuticals CE FERULIC
Description: Test Side receives SkinCeuticals A.G.E and Skinceuticals CE FERULIC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cream
Description: Control Side applies Standard Cream